Understanding Non-Binding Advisory Recommendations at Federal Agencies

Advice vs. decision

Federal advisory committees exist to give agencies access to external expertise. By design, many of their outputs are **recommendations**: structured advice that the parent agency may accept, reject, or modify when it takes final action.

FDA’s Pharmacy Compounding Advisory Committee fits that model for 503A bulks questions. A committee vote becomes part of the administrative record. It does not rewrite the Code of Federal Regulations on meeting day.

Why agencies keep recommendations non-binding

Non-binding advice preserves:

- Statutory accountability (the agency, not the panel, owns the final action)

- Room for full notice-and-comment rulemaking

- Ability to weigh staff scientific reviews alongside public filings

- Consistency with ethics and administrative-procedure norms

If every advisory vote automatically became law, the distinction between advice and regulation would collapse.

Historical pattern in compounding

Stakeholder comments on the PCAC process have noted that FDA staff frequently recommend against adding nominated substances, that the committee sometimes votes the other way, and that final rules can lag for years. Separate reporting has also described at least one case where FDA did not ultimately add a substance despite a favorable committee recommendation.

The pattern is not “committee equals listing.” The pattern is “committee advises; FDA’s later action is the binding step.”

How to quote advisory outcomes responsibly

- State the vote as a recommendation

- Note staff positions when they differ

- Point to the next procedural milestones (NPRM, comments, final rule)

- Avoid verbs like “approved,” “legalized,” or “cleared” unless a final agency action actually did that

Accurate verbs are a compliance control as much as an editorial preference.

*For research use only. Not for human or animal consumption.*